Ziritaxestat
Idiopathic Pulmonary Fibrosis · Autotaxin/LPA1
Clinical trials
1
Mechanism
Autotaxin/LPA1
Developer
Galapagos
Overview
Ziritaxestat is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via autotaxin/lpa1. It appears in 1 tracked IPF clinical trial.
Ziritaxestat clinical trials
Explore related
Medical disclaimer. This page summarizes research about Ziritaxestat for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.